Importer of Controlled Substances; Notice of Application; Hospira, 151 [2013-31364]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 1 / Thursday, January 2, 2014 / Notices
151
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Hospira
maindgalligan on DSK5TPTVN1PROD with NOTICES
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Application;
American Radiolabeled Chemicals, Inc.
Dated: December 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–31362 Filed 12–31–13; 8:45 am]
Pursuant to 21 CFR 1301.34(a), this is
notice that on September 25, 2013,
Hospira, 1776 North Centennial Drive,
McPherson, Kansas 67460–1247, made
application by renewal to the Drug
Enforcement Administration (DEA) for
registration as an importer of
Remifentanil (9739), a basic class of
controlled substance listed in schedule
II.
The company plans to import
Remifentanil for use in dosage form
manufacturing.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 3, 2014.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: December 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–31364 Filed 12–31–13; 8:45 am]
Pursuant to 21 CFR 1301.33(a), this is
notice that on October 24, 2013,
American Radiolabeled Chemicals, Inc.,
101 Arc Drive, St. Louis, Missouri
63146, made application by written
correspondence to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Methadone (9250), a basic class of
controlled substance in schedule II.
The company plans to manufacture
small quantities of the listed controlled
substance as radiolabeled compounds
for biochemical research.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than March 3, 2014.
Dated: December 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–31363 Filed 12–31–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Boehringer Ingelheim Chemicals, Inc.;
Correction
In Federal Register (FR DOC) 2013–
25096 on page 64019, in the issue of
Friday, October 25, 2013, make the
following corrections:
On page 64019, in the first column, in
the table, the first cell inadvertently
omitted basic class of controlled
substance Amphetamine (1100), and the
second column, in the table, the last
cells should read ‘‘II’’.
BILLING CODE 4410–09–P
VerDate Mar<15>2010
17:20 Dec 31, 2013
Jkt 232001
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
BILLING CODE 4410–09–P
NATIONAL ARCHIVES AND RECORDS
ADMINISTRATION
[NARA–2014–013]
Records Schedules; Availability and
Request for Comments
National Archives and Records
Administration (NARA).
ACTION: Notice of availability of
proposed records schedules; request for
comments.
AGENCY:
The National Archives and
Records Administration (NARA)
publishes notice at least once monthly
of certain Federal agency requests for
records disposition authority (records
schedules). Once approved by NARA,
records schedules provide mandatory
instructions on what happens to records
when no longer needed for current
Government business. They authorize
the preservation of records of
continuing value in the National
Archives of the United States and the
destruction, after a specified period, of
records lacking administrative, legal,
research, or other value. Notice is
published for records schedules in
which agencies propose to destroy
records not previously authorized for
disposal or reduce the retention period
of records already authorized for
disposal. NARA invites public
comments on such records schedules, as
required by 44 U.S.C. 3303a(a).
DATES: Requests for copies must be
received in writing on or before
February 3, 2014. Once the appraisal of
the records is completed, NARA will
send a copy of the schedule. NARA staff
usually prepares appraisal
memorandums that contain additional
information concerning the records
covered by a proposed schedule. These,
too, may be requested and will be
provided once the appraisal is
completed. Requesters will be given 30
days to submit comments.
ADDRESSES: You may request a copy of
any records schedule identified in this
notice by contacting Records
Management Services (ACNR) using one
of the following means:
Mail: NARA (ACNR), 8601 Adelphi
Road, College Park, MD 20740–6001.
Email: request.schedule@nara.gov.
FAX: 301–837–3698.
SUMMARY:
E:\FR\FM\02JAN1.SGM
02JAN1
]]>Agencies
[Federal Register Volume 79, Number 1 (Thursday, January 2, 2014)]
[Notices]
[Page 151]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-31364]
[[Page 151]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application; Hospira
Pursuant to 21 CFR 1301.34(a), this is notice that on September 25,
2013, Hospira, 1776 North Centennial Drive, McPherson, Kansas 67460-
1247, made application by renewal to the Drug Enforcement
Administration (DEA) for registration as an importer of Remifentanil
(9739), a basic class of controlled substance listed in schedule II.
The company plans to import Remifentanil for use in dosage form
manufacturing.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43, and in
such form as prescribed by 21 CFR 1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODW), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than February 3, 2014.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substance in
schedules I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: December 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-31364 Filed 12-31-13; 8:45 am]
BILLING CODE 4410-09-P
